Evaluation of Fibrinogen, Haemoglobin and Platelet Indices in Patients with Alzheimer’s Disease in Imo State
DOI:
https://doi.org/10.64137/31079377/IJMSD-V1I2P103Keywords:
Fibrinogen, Haemoglobin, Platelet indices, Alzheimer’s diseaseAbstract
Finding reliable, less intrusive biomarkers for the early diagnosis and monitoring of Alzheimer's disease (AD) is still a big scientific problem. This study assessed fibrinogen, haemoglobin, and platelet indices in patients with Alzheimer's disease at Imo Specialist Hospital, Owerri, Nigeria. A total of 60 volunteers were included, consisting of 30 clinically confirmed Alzheimer's disease patients and 30 age-matched ostensibly healthy controls. We took 7 mL of blood from each person: 2 mL went into EDTA bottles for blood tests and 5 mL went into plain bottles for serum separation. The samples were spun in a centrifuge at 3,000 rpm for 5 minutes, and the sera were kept at −20°C until they were ready to be looked at. We used the clot-based approach to find fibrinogen, the cyanmethemoglobin method to get haemoglobin, and an automated haematology analyser to find platelet indices. We used SPSS version 27 to look at the data. We found the mean values, standard deviations, Student's t-test, Pearson correlation, and p-values.Mean haemoglobin (10.33 ± 1.39 g/dL), platelet count (178.77 ± 47.46 ×10⁹/L), PDW (16.00 ± 3.22%), and PCT (0.17 ± 0.05%) were significantly lower in Alzheimer’s patients compared with controls (12.79 ± 0.94 g/dL, 307.63 ± 87.76 ×10⁹/L, 18.75 ± 4.41%, and 0.24 ± 0.07%, respectively; p < 0.05). On the other hand, MPV (9.25 ± 1.06 fL), P-LCR (20.57 ± 6.79%), and fibrinogen (472.60 ± 91.59 mg/dL) were much greater in AD patients than in controls (p < 0.05). There were no significant differences in any parameter according to age or gender. Haemoglobin had substantial positive relationships with platelet count and PCT, and a significant negative link with fibrinogen. Alzheimer's disease is linked to anaemia, platelet irregularities, and increased fibrinogen levels, indicating that hypoxia, platelet activation, and inflammation are significant factors in the illness's aetiology. These metrics may function as accessible biomarkers for the surveillance of Alzheimer’s disease.
References
[1] B. Borroni et al., “Microvascular damage and platelet abnormalities in early Alzheimer’s disease,” Journal of the Neurological Sciences, vol. 203–204, pp. 189–193, Nov. 2002, doi: https://doi.org/10.1016/s0022-510x(02)00289-7.
[2] H. Zhang and Z. Zhou, “Fibrinogen in Alzheimer’s Disease, Parkinson’s Disease and Lewy Body Dementia: A Mendelian Randomization Study,” Frontiers in Aging Neuroscience, vol. 14, Jul. 2022, doi: https://doi.org/10.3389/fnagi.2022.847583.
[3] C. Jie, V. Treyer, R. Schibli, and L. Mu, “TauvidTM: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease,” Pharmaceuticals, vol. 14, no. 2, p. 110, Jan. 2021, doi: https://doi.org/10.3390/ph14020110.4.
[4] D. S. Knopman et al., “Alzheimer disease,” Nature Reviews Disease Primers, vol. 7, no. 1, May 2021, doi: https://doi.org/10.1038/s41572-021-00269-y.
[5] Z. Breijyeh and R. Karaman, “Comprehensive Review on Alzheimer’s Disease: Causes and Treatment,” Molecules, vol. 25, no. 24, p. 5789, Dec. 2020, doi: https://doi.org/10.3390/molecules25245789.
[6] S. G. CHU et al., “Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis,” Journal of Thrombosis and Haemostasis, vol. 8, no. 1, pp. 148–156, Jan. 2010, doi: https://doi.org/10.1111/j.1538-7836.2009.03584.x.
[7] R. S. Desikan et al., “Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer’s disease,” Brain, vol. 132, no. 8, pp. 2048–2057, May 2009, doi: https://doi.org/10.1093/brain/awp123.
[8] P. T. Kotzbauer, J. Q. Tojanowski, and V. M. V. Lee, “Lewy Body Pathology in Alzheimer’s Disease,” Journal of Molecular Neuroscience, vol. 17, no. 2, pp. 225–232, 2001, doi: https://doi.org/10.1385/jmn:17:2:225.
[9] N. I. Bradfield and D. Ames, “Mild cognitive impairment: narrative review of taxonomies and systematic review of their prediction of incident Alzheimer’s disease dementia,” BJPsych Bulletin, pp. 1–8, Nov. 2019, doi: https://doi.org/10.1192/bjb.2019.77
[10] Salminen, A. Kauppinen, and K. Kaarniranta, “Hypoxia/ischemia activate processing of Amyloid Precursor Protein: impact of vascular dysfunction in the pathogenesis of Alzheimer’s disease,” Journal of Neurochemistry, vol. 140, no. 4, pp. 536–549, Feb. 2017, doi: https://doi.org/10.1111/jnc.13932.
[11] D. Davalos and K. Akassoglou, “Fibrinogen as a key regulator of inflammation in disease,” Seminars in Immunopathology, vol. 34, no. 1, pp. 43–62, Oct. 2011, doi: https://doi.org/10.1007/s00281-011-0290-8.
[12] K. Gauthreaux et al., ‘Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy,” Journal of Neuropathology and Experimental Neurology, vol. 79, no. 5, pp. 465-473, Feb. 2020, doi: https://doi.org/10.1093/jnen/nlaa014
[13] F. T. Hane, M. Robinson, B. Y. Lee, O. Bai, Z. Leonenko, and M. S. Albert, “Recent Progress in Alzheimer’s Disease Research, Part 3: Diagnosis and Treatment,” Journal of Alzheimer’s Disease, vol. 57, no. 3, pp. 645–665, Apr. 2017, doi: https://doi.org/10.3233/jad-160907.
[14] M. A. Altinöz, Sinan Gülöksüz, Rainald Schmidt‐Kastner, G. Kenis, Bahri İnce, and Bart, “Involvement of hemoglobins in the pathophysiology of Alzheimer’s disease,” Experimental Gerontology, vol. 126, pp. 110680–110680, Oct. 2019, doi: https://doi.org/10.1016/j.exger.2019.110680.
[15] J. S. Birks and R. J. Harvey, “Donepezil for dementia due to Alzheimer’s disease,” Cochrane Database of Systematic Reviews, vol. 2, no. 6, Jun. 2018, doi: https://doi.org/10.1002/14651858.cd001190.pub3.
[16] Z. Zhang, M. Wang, and X. Liu, “C-reactive protein and risk of Alzheimer’s disease,” Neurobiology of Aging, vol. 109, pp. 259–263, Jan. 2022, doi: https://doi.org/10.1016/j.neurobiolaging.2021.08.010.
[17] T. Lott and E. Head, “Dementia in Down syndrome: unique insights for Alzheimer disease research,” Nature Reviews Neurology, vol. 15, no. 3, pp. 135–147, Feb. 2019, doi: https://doi.org/10.1038/s41582-018-0132-6.
[18] Scheltens, Philip et al., “Alzheimer's disease,” The Lancet, vol. 397, no. 10284, pp. 1577 – 1590, 2021.
[19] R. C. Shah, A. S. Buchman, R. S. Wilson, S. E. Leurgans, and D. A. Bennett, “Hemoglobin level in older persons and incident Alzheimer disease: Prospective cohort analysis,” Neurology, vol. 77, no. 3, pp. 219–226, Jul. 2011, doi: https://doi.org/10.1212/wnl.0b013e318225aaa9.
[20] Viña and J. Sanz‐Ros, “Alzheimer’s disease: Only prevention makes sense,” European Journal of Clinical Investigation, vol. 48, no. 10, pp. 1–1, Oct. 2018, doi: https://doi.org/10.1111/eci.13005.
[21] Weller and A. Budson, “Current understanding of Alzheimer’s disease diagnosis and treatment,” F1000Research, vol. 7, no. 1, p. 1161, Jul. 2018, doi: https://doi.org/10.12688/f1000research.14506.1.
[22] P. C. Guest, Ed., Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders. Cham: Springer International Publishing, 2019. doi: https://doi.org/10.1007/978-3-030-05542-4.
[23] C. Rosendorff, M. S. Beeri, and J. M. Silverman, “Cardiovascular Risk Factors for Alzheimer’s Disease,” The American Journal of Geriatric Cardiology, vol. 16, no. 3, pp. 143–149, Mar. 2007, doi: https://doi.org/10.1111/j.1076-7460.2007.06696.x.
[24] D. Hsu and G. Marshall, “Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward,” Current Alzheimer Research, vol. 13, no. 999, pp. 1–1, Sep. 2016, doi: https://doi.org/10.2174/1567205013666160930112125.
[25] J. M. Long and D. M. Holtzman, “Alzheimer Disease: An Update on Pathobiology and Treatment Strategies,” Cell, vol. 179, no. 2, pp. 312–339, Oct. 2019, doi: https://doi.org/10.1016/j.cell.2019.09.001.
[26] W. J. Deardorff and G. T. Grossberg, “Behavioral and Psychological Symptoms in Alzheimer’s Dementia and Vascular Dementia,” Psychopharmacology of Neurologic Disease, vol. 165, pp. 5–32, 2019, doi: https://doi.org/10.1016/b978-0-444-64012-3.00002-2.
[27] J.-T. Yu et al., “Evidence-based prevention of Alzheimer’s disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 91, no. 11, pp. 1201–1209, Nov. 2020, doi: https://doi.org/10.1136/jnnp-2019-321913.
